Maze Therapeutics to Participate in Two Upcoming Investor Conferences
Maze Therapeutics (NASDAQ:MAZE), a clinical-stage biopharmaceutical company focused on developing precision medicines for renal, metabolic and cardiovascular diseases, has announced its participation in two upcoming investor conferences in July 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Maze Therapeutics (NASDAQ:MAZE), a clinical-stage biopharmaceutical company focused on developing precision medicines for renal, metabolic and cardiovascular diseases, has announced its participation in two upcoming investor conferences in July 2025.
Management will participate in fireside chats at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14 at 2:30 p.m. ET and the BTIG Virtual Biotech Conference on July 30 at 9:20 a.m. ET. Webcasts will be available on the company's website and archived for 60 days.
Details
News Market Reaction – MAZE
The recorded move for MAZE in the trading session of this news was -3.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that company management will participate in fireside chats during two upcoming investor conferences in July:
- H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025, at 2:30 p.m. ET
- BTIG Virtual Biotech Conference on Wednesday, July 30, 2025, at 9:20 a.m. ET
Live webcasts of the events will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentations.
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups. The company’s pipeline is led by two wholly owned programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for patients. For more information, please visit mazetx.com, or follow the company on LinkedIn and X.
IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com
Media Contact:
Amanda Lazaro, 1AB
amanda@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.